A phase II trial shows that a chemotherapy-free regimen of dasatinib and 
blinatumomab produces molecular responses in patients with Philadelphia 
chromosome-positive acute lymphoblastic leukemia. The study found that 60% of 
patients had molecular responses after two cycles of blinatumomab and 71% had 
molecular responses after five cycles.